KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $24.2 million.

  • Amneal Pharmaceuticals' Receivables - Other rose 20808.4% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 20808.4%. This contributed to the annual value of $9.1 million for FY2024, which is 792.63% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Receivables - Other of $24.2 million as of Q3 2025, which was up 20808.4% from $16.3 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Other peaked at $100.0 million during Q2 2022, and registered a low of $30000.0 during Q1 2023.
  • For the 5-year period, Amneal Pharmaceuticals' Receivables - Other averaged around $25.4 million, with its median value being $15.1 million (2023).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Receivables - Other plummeted by 9993.65% in 2023 and then skyrocketed by 4257333.33% in 2024.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Other (Quarter) stood at $1.2 million in 2021, then skyrocketed by 2710.26% to $33.1 million in 2022, then tumbled by 70.03% to $9.9 million in 2023, then fell by 7.93% to $9.1 million in 2024, then skyrocketed by 164.71% to $24.2 million in 2025.
  • Its last three reported values are $24.2 million in Q3 2025, $16.3 million for Q2 2025, and $20.5 million during Q1 2025.